MedTrace Logo

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

NCT05657418 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-06-06

No results posted yet for this study

Summary

The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced pancreatic cancer.

Conditions

  • Advanced Pancreatic Cancer

Interventions

DRUG

JS107

JS107, i.v., q3w

COMBINATION_PRODUCT

JS107 combination with Toripalimab

JS107 i.v., q3w combine with Toripalimab

Sponsors & Collaborators

  • Shanghai Junshi Bioscience Co., Ltd.

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-29
Primary Completion
2025-01-04
Completion
2025-01-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05657418 on ClinicalTrials.gov